International Society for the Study of Women's Sexual Health

General Statement of the International Society for the Study of Women's Sexual Health

The International Society for the Study of Women's Sexual Health (ISSWSH), the preeminent scientific organization focused on research, education, and clinical practice of women's sexuality, applauds the FDA's recent announcement of it's upcoming Joint Meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee on June 4, 2015.

The meeting culminates the prolonged development of flibanserin, a drug that could be the first approved medical treatment for distressing low sexual desire. Flibanserin offers a favorable safety and efficacy profile for the treatment of Hypoactive Sexual Desire Disorder in women. While we fully endorse the FDA's evidence-based review of the risks and benefits of this treatment, ISSWSH wishes to emphasize the significant unmet need for safe and effective medical therapies to address all women's sexual problems.

Save the Date

ISSWSH Fall Course 2019
November 14-16, 2019   22 days left
DoubleTree Hilton Hotel, Scottsdale, AZ - USA
Read more...

ISSWSH Annual Meeting 2020
March 5-8, 2020   134 days left
Renaissance Orlando at Seaworld, Orlando, FL, USA

ISSWSH Sexual Pain Course 2020
April 17-18, 2020 134 days left
Georgetown University Medical Center, Medical and Dental Building, Washington, DC, USA

ISSWSH Annual Meeting 2021
March 4-7, 2021   498 days left
Renaissance Dallas Hotel, Dallas, TX, USA

Latest Tweets

Sexually transmitted infections are on the rise, here is one OB/GYNs opinion of why we cannot "shake the stigma" https://t.co/lbG3NRj6nG ISSWSH
Laser Doppler imaging has recently been applied to the study of female sexual response, with promising results. .… https://t.co/GKWYh3vghS ISSWSH

Contact Details

ISSWSH Executive Office
14305 Southcross Dr
Suite 100
Burnsville, MN 55306
USA

Phone: +1 (952) 683 9025
Fax: +1 (952) 314 8212
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Follow us on Twitter!